Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $480 From $440
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $566 From $500
Vertex Pharmaceuticals Analyst Ratings
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating
Vertex Pharmaceuticals Analyst Ratings
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402
Vertex Pharmaceuticals Analyst Ratings
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540
Vertex Pharmaceuticals Analyst Ratings
Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465
Vertex Pharmaceuticals Analyst Ratings
RBC Adjusts Price Target on Vertex Pharmaceuticals to $421 From $424
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Vertex Pharmaceuticals (VRTX) and Guardant Health (GH)
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497